Anticancer agent 44 

Anticancer agent 44 (compound 2a) is a potent anticancer agent. Anticancer agent 44 shows cytotoxicity activity in cancer cells. Anticancer agent 44 induces apoptosis. Anticancer agent 44 shows low toxicity towards activated lymphocytes of human blood^[1].

Anticancer agent 44 (compound 2a) (0-100 µM; 72 h) shows antitumor activity with GI₅₀s of 3.40, 63.90, 7.95, 6.45, 70.30, 6.65, 9.18, 6.00, 8.93, 65.90, >100 µM for Jurkat, A549, MCF-7, MDA-MB-231, KB3-1, HeLa, HCT-116, HCT-116 p53-/-, U251, SK-OV-3, HaCaT cells, respectively^[1].
Anticancer agent 44 (1.5 µM; 24 h) induces apoptosis by increases the expression of caspase 3, Bax and decreases the amount of anti-apoptotic Bcl-2 protein^[1].
Anticancer agent 44 (0-2 µM; 24, 48 h) shows low toxicity towards normal human keratinocytes of HaCaT line and mitogen-activated lymphocytes of peripheral blood of healthy human donor^[1].
Anticancer agent 44 dose not induce significant DNA damage and changes in morphology of mitogen-activated lymphocytes of peripheral blood of healthy donor^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

534.39

C₂₂H₁₃Cl₂N₃O₅S₂

2770943-86-5

O=C1CC(C(N1C2=CC=C(C=C2)Cl)=O)N3C(/C(SC3=S)=C/C(Cl)=C/C4=CC=C(C=C4)[N+]([O-])=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Nataliya Finiuk, et al. Novel hybrid pyrrolidinedione-thiazolidinones as potential anticancer agents: Synthesis and biological evaluation. Eur J Med Chem. 2022 May 2;238:114422.  [Content Brief]

  [2]. Finiuk N, et al. Novel hybrid pyrrolidinedione-thiazolidinones as potential anticancer agents: Synthesis and biological evaluation. Eur J Med Chem. 2022 May 2;238:114422.